Literature DB >> 12545262

Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume.

M R Harrigan1, S R Ennis, S E Sullivan, R F Keep.   

Abstract

BACKGROUND: Therapeutic cerebral angiogenesis, utilizing angiogenic factors to enhance collateral vessel formation within the central nervous system, is a potential method for cerebral revascularization. A prior dose-response study determined that intracerebroventricular infusion of vascular endothelial growth factor (VEGF) increases vascular density with minimal associated brain edema at a concentration of 5 microg/ml. The purpose of this study was to assess effects of intracerebroventricular infusion of VEGF (5 microg/ml) on cerebral blood flow, infarct volume, and brain edema after ischemia.
METHODS: Recombinant human VEGF(165) was infused into the right lateral ventricle of rats with an osmotic minipump at a rate of 1 microl/hr for 7 days. Control animals received vehicle only. Ischemia was produced by transient (2 hours) middle cerebral artery occlusion (MCAO). After MCAO, cerebral blood flow was determined with the indicator fractionation technique: infarct volume was assessed with 2,3,5-triphenlytetrazolium chloride staining, and brain edema was determined by measuring brain water content.
FINDINGS: Cerebral blood flow was not significantly different in animals treated with VEGF compared to controls. There was a significant reduction in total infarct volume after temporary MCAO in VEGF-treated animals compared to controls (163+/-37 mm(3) vs. 309+/-54 mm(3), P<0.05). Brain water content after transient MCAO was also significantly reduced in VEGF-treated animals compared to controls (80.9+/-0.7% vs. 83.3+/-0.6%, P<0.05).
INTERPRETATION: Intracerebroventricular infusion of VEGF(165) (5 microg/ml) decreases infarct volume and brain edema after temporary MCAO without a significant increase in cerebral blood flow. These results indicate that VEGF may have a direct neuroprotective effect in cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12545262     DOI: 10.1007/s00701-002-1035-1

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  26 in total

1.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

2.  Sustained expression of vascular endothelial growth factor and angiopoietin-1 improves blood-spinal cord barrier integrity and functional recovery after spinal cord injury.

Authors:  Juan J Herrera; Laura M Sundberg; Lorena Zentilin; Mauro Giacca; Ponnada A Narayana
Journal:  J Neurotrauma       Date:  2010-10-28       Impact factor: 5.269

3.  Engineered stem cell mimics to enhance stroke recovery.

Authors:  Paul M George; Byeongtaek Oh; Ruby Dewi; Thuy Hua; Lei Cai; Alexa Levinson; Xibin Liang; Brad A Krajina; Tonya M Bliss; Sarah C Heilshorn; Gary K Steinberg
Journal:  Biomaterials       Date:  2018-06-14       Impact factor: 12.479

4.  Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.

Authors:  Edward M Conway; Femke Zwerts; Veerle Van Eygen; Astrid DeVriese; Nobuo Nagai; Wei Luo; Désiré Collen
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

Review 6.  Neuroprotection in the newborn infant.

Authors:  Fernando F Gonzalez; Donna M Ferriero
Journal:  Clin Perinatol       Date:  2009-12       Impact factor: 3.430

7.  Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.

Authors:  Koen Poesen; Diether Lambrechts; Philip Van Damme; Joke Dhondt; Florian Bender; Nicolas Frank; Elke Bogaert; Bart Claes; Line Heylen; An Verheyen; Katrien Raes; Marc Tjwa; Ulf Eriksson; Masabumi Shibuya; Rony Nuydens; Ludo Van Den Bosch; Theo Meert; Rudi D'Hooge; Michael Sendtner; Wim Robberecht; Peter Carmeliet
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

Review 8.  VEGF: a critical player in neurodegeneration.

Authors:  Erik Storkebaum; Peter Carmeliet
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 9.  Help-me signaling: Non-cell autonomous mechanisms of neuroprotection and neurorecovery.

Authors:  Changhong Xing; Eng H Lo
Journal:  Prog Neurobiol       Date:  2016-04-11       Impact factor: 11.685

10.  Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.

Authors:  Torsten Falk; Shiling Zhang; Scott J Sherman
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.